SCHEMBL21389590

SCHEMBL21389590

CCn1c(CSc2nc(O)c3c(C)cc(C)nc3n2)nc2c1c(=O)[nH]c(=O)n2Cc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 4/20 0.61
▸ BRD2 P25440 3/20 0.61
▸ BRD3 Q15059 3/20 0.61
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ HPGD P15428 4/20 0.44
▸ TSHR P16473 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ PSMD14 O00487 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ BRDT Q58F21 2/20 0.42
▸ ALDH1A1 P00352 5/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TPH1 P17752 4/20 0.40
▸ TPH2 Q8IWU9 4/20 0.40
▸ ATM Q13315 1/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ HSD17B10 Q99714 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19090219 0.93 BRD4 (0.52) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL19090310 0.85 BRD4 (0.53) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL19090215 0.78 BRD4 (0.72) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL19090233 0.77 BRD4 (0.34) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL21389558 0.77 BRD4 (0.73) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL19066325 0.76 BRD4 (1.00) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL21389479 0.75 BRD4 (0.58) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL21389578 0.74 MEN1 (0.83) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL21389544 0.73 BRD4 (0.63) BRD4BRD2BRD3MEN1KMT2A
SCHEMBL21389579 0.73 MEN1 (0.66) BRD4BRD2BRD3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225481-B2 Xanthine derivative inhibitors of BET proteins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-01-18 — — US disclosed
EP-3397640-B1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INST NAT SANTE RECH MED (FR) 2021-08-04 — — EP disclosed
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS BET1, BRD4, BRD3 BRD4 2/4885BRD2 6/4885BRD3 3/4885
US-11225481-B2 Xanthine derivative inhibitors of BET proteins BET1, BRD4, BRD3 BRD4 2/4885BRD2 6/4885BRD3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback